Sector News

Nestle pushes further into health science with Seres investment

January 7, 2015
Life sciences
(Reuters) – Nestle Health Science has invested $65 million in U.S.-based drugmaker Seres Health Inc, the latest move by its parent company Nestle to diversify away from packaged food.
 
Nestle has been expanding its reach into the fast-growing market for healthcare products that have higher margins than the instant soups, breakfast cereals and coffee the world’s biggest food group is generally known for.
 
The investment will help fund the next stage of development of Seres’ lead product candidate against clostridium difficile infection (CDI) – a bacterial infection of the digestive system – into late-stage clinical trials and help advance its other treatments against infectious, metabolic and inflammatory diseases, Nestle said on Tuesday.
 
Nestle Health Science also said on Tuesday it had entered into a strategic partnership with Seres’ venture capital backer, Flagship Ventures, to support start-ups working on nutritional health and therapy in view of potential further minority direct investments, licensing deals, joint ventures or acquisitions.
 
Nestle set up Nestle Health Science in 2011 to develop new therapeutic approaches for gastrointestinal, metabolic and brain disorders and other health conditions.
 
(Reporting by Silke Koltrowitz; editing by Susan Thomas)

Related News

September 30, 2020

Johnson & Johnson signs on Michigan’s Grand River to help with COVID-19 vaccine finishing work

Life sciences

With all eyes on the hunt for a COVID-19 vaccine, drugmakers like New Jersey’s Johnson & Johnson are scouring the market for manufacturing partners to help meet what would be […]

September 30, 2020

Takeda taps Elektrofi’s microparticle delivery platform for potential subq plasma offerings

Life sciences

Takeda has joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could enable simpler dosing with plasma-derived therapies. Takeda will assess Elektrofi’s drug delivery platform using […]

September 29, 2020

Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion

Life sciences

Novo Nordisk wants the heart disease community to join the diabetes conversation. As Type 2 diabetes drugs nab approvals for reduced cardiovascular risks—including Novo’s own Ozempic and Victoza—the need to […]